ArticleCancer gene therapy2008
Resveratrol is an effective inducer of CArG-driven TNF-alpha gene therapy.
Article in Cancer gene therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- MicroRNA-181a in acute lymphoblastic leukemia: expression pattern, target genes and its potential as a biomarker.Biochemistry and biophysics reports · 2026Review
- Quercetin selectively targets gingival squamous cell carcinoma through apoptosis induction, autophagy suppression, DNA damage, and chemosensitization.Frontiers in oncology · 2026Article
- Resveratrol DeliveryTurkish journal of pharmaceutical sciences · 2022Article
- The Role of the Transcription Factor EGR1 in Cancer.Frontiers in oncology · 2021Review
- Friend or foe, the role of EGR-1 in cancer.Medical oncology (Northwood, London, England) · 2019Review
- Resveratrol and siRNA in combination reduces Hsp27 expression and induces caspase-3 activity in human glioblastoma cells.Cell stress & chaperones · 2019Article
- GADD45α-targeted suicide gene therapy driven by synthetic CArG promoter E9NS sensitizes NSCLC cells to cisplatin, resveratrol, and radiation regardless of p53 status.OncoTargets and therapy · 2019Article
- Anticancer Molecular Mechanisms of Resveratrol.Frontiers in nutrition · 2016Review
- CArG-driven GADD45α activated by resveratrol inhibits lung cancer cells.Genes & cancer · 2015Article
- An oncolytic adenovirus regulated by a radiation-inducible promoter selectively mediates hSulf-1 gene expression and mutually reinforces antitumor activity of I131-metuximab in hepatocellular carcinoma.Molecular oncology · 2013Article
- Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons.Nature reviews. Drug discovery · 2012Review
- Chapter seven--Cancer treatment with gene therapy and radiation therapy.Advances in cancer research · 2012Review
- Resveratrol inhibits Cdk5 activity through regulation of p35 expression.Molecular pain · 2011Article
- Transcriptional control of Flt3 ligand targeted by fluorouracil-induced Egr-1 promoter in hematopoietic damage.Journal of biomedical science · 2009Article
- Is EGR1 a potential target for prostate cancer therapy?Future oncology (London, England) · 2009Review
- Tumor necrosis factor and cancer, buddies or foes?Acta pharmacologica Sinica · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
We report the anticarcinogenic, anti-aging polyphenol resveratrol activates the radio- and chemo-inducible cancer gene therapy vector Ad.Egr.TNF, a replication-deficient adenovirus that expresses human tumor necrosis factor alpha (TNF-alpha) under control of the Egr-1 promoter. Like ionizing radiation or chemotherapeutic agents previously shown to activate Ad.Egr.TNF, resveratrol also induces Egr-1 expression from its chromosomal locus with a possible role for Egr-1 promoter CC(A+T)richGG sequences in the expression of TNF-alpha. Resveratrol induction of TNF-alpha in Ad.Egr.TNF-infected tumor xenografts demonstrated antitumor response in human and rat tumor models comparable to that of radio- or chemotherapy-induced TNF-alpha. Although sirtuins are known targets of resveratrol, in vitro inhibition of SIRT1 activity did not abrogate resveratrol induction of Egr-1 expression. This suggests that SIRT1 is not essential to mediate resveratrol induction of Egr-1. Nevertheless, control of transgene expression via resveratrol activation of Egr-1 may extend use of Ad.Egr.TNF to patients intolerant of radiation or cytotoxic therapy and offer a novel tool for development of other inducible gene therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.